LifeStance Health Group (NASDAQ:LFST) Given New $9.00 Price Target at BTIG Research

LifeStance Health Group (NASDAQ:LFST) had its target price boosted by equities researchers at BTIG Research from $8.00 to $9.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. BTIG Research’s price target indicates a potential upside of 51.90% from the stock’s current price.

LFST has been the topic of several other research reports. Wall Street Zen lowered LifeStance Health Group from a “buy” rating to a “hold” rating in a report on Saturday, October 11th. Weiss Ratings restated a “sell (e+)” rating on shares of LifeStance Health Group in a report on Wednesday, October 8th. Zacks Research downgraded LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a report on Wednesday. Finally, UBS Group upped their target price on shares of LifeStance Health Group from $8.50 to $9.00 and gave the company a “buy” rating in a research report on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $8.67.

LifeStance Health Group Stock Performance

Shares of NASDAQ:LFST traded down $0.33 on Thursday, hitting $5.93. 1,347,145 shares of the company were exchanged, compared to its average volume of 1,978,617. The company’s 50 day moving average price is $5.29 and its two-hundred day moving average price is $5.27. LifeStance Health Group has a one year low of $3.74 and a one year high of $8.30. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.48 and a current ratio of 1.48. The firm has a market capitalization of $2.30 billion, a price-to-earnings ratio of -118.50 and a beta of 1.15.

LifeStance Health Group (NASDAQ:LFST) last released its earnings results on Thursday, November 6th. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.01) by $0.03. LifeStance Health Group had a negative net margin of 1.23% and a negative return on equity of 1.11%. The business had revenue of $363.81 million during the quarter, compared to analysts’ expectations of $355.06 million. During the same quarter last year, the company earned ($0.02) earnings per share. The firm’s revenue was up 16.3% on a year-over-year basis. LifeStance Health Group has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. Research analysts expect that LifeStance Health Group will post -0.18 earnings per share for the current year.

Insider Transactions at LifeStance Health Group

In other LifeStance Health Group news, major shareholder Silversmith Partners I. Gp, Llc sold 3,592,357 shares of the firm’s stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $5.07, for a total transaction of $18,213,249.99. Following the sale, the insider directly owned 14,324,197 shares in the company, valued at approximately $72,623,678.79. This trade represents a 20.05% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Darren M. Black sold 8,407,643 shares of the company’s stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $5.07, for a total transaction of $42,626,750.01. Following the completion of the transaction, the director owned 33,524,715 shares of the company’s stock, valued at $169,970,305.05. This trade represents a 20.05% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 20,407,643 shares of company stock valued at $103,466,750 over the last 90 days. 3.20% of the stock is owned by company insiders.

Institutional Trading of LifeStance Health Group

Institutional investors have recently modified their holdings of the company. Choreo LLC raised its stake in LifeStance Health Group by 6.4% in the first quarter. Choreo LLC now owns 27,420 shares of the company’s stock valued at $183,000 after buying an additional 1,661 shares during the period. Invesco Ltd. lifted its position in shares of LifeStance Health Group by 1.4% in the 1st quarter. Invesco Ltd. now owns 164,384 shares of the company’s stock worth $1,095,000 after purchasing an additional 2,238 shares during the period. Vident Advisory LLC raised its position in shares of LifeStance Health Group by 12.7% in the 2nd quarter. Vident Advisory LLC now owns 21,732 shares of the company’s stock worth $112,000 after acquiring an additional 2,447 shares in the last quarter. State of Wyoming grew its holdings in LifeStance Health Group by 3.8% in the third quarter. State of Wyoming now owns 89,927 shares of the company’s stock worth $495,000 after purchasing an additional 3,298 shares during the period. Finally, Legal & General Group Plc grew its stake in LifeStance Health Group by 2.4% in the second quarter. Legal & General Group Plc now owns 144,263 shares of the company’s stock valued at $746,000 after acquiring an additional 3,331 shares during the period. 85.50% of the stock is currently owned by institutional investors.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.